Belite Bio (BLTE) Depreciation & Amortization (CF) (2024 - 2025)
Belite Bio (BLTE) recorded quarterly Depreciation & Amortization (CF) of $45000.0 in Q4 2025, up 4.65% quarter-over-quarter from $43000.0 in Q4 2024, and up 4.65% on a YoY basis from $43000.0 in Q4 2024.
Belite Bio (BLTE) Depreciation & Amortization (CF) (2024 - 2025) Analysis & Trends
Belite Bio's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $45000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 4.65% year-over-year to $45000.0; the TTM figure through Mar 2026 stood at $45000.0 (up 4.65% YoY), while the FY2025 annual figure was $464000.0, up 3.34% from the prior year.
- Depreciation & Amortization (CF) was $45000.0 for Q4 2025 at Belite Bio, up from $43000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $45000.0 in Q4 2025 to a low of $43000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 123.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45,000.00 |
| Dec 31, 2025 | 45,000.00 |
| Dec 31, 2024 | 43,000.00 |
| Dec 31, 2024 | 43,000.00 |